Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

26 Nov 2023

Abstract excerpt

Background T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants. Method: We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human trial in healthy adults. Here, we report on long-term safety and efficacy data of CoVac-1 until month 12. Results CoVac-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38016500
DOI: 10.1016/j.ijid.2023.11.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsPMID 38016500Read ↗

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsSemantic proximity Read ↗

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencySemantic proximity Read ↗

Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell ImmunitySemantic proximity Read ↗

Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccineSemantic proximity Read ↗

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validationSemantic proximity Read ↗

SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19Semantic proximity Read ↗

An Overview of the Immune Response to COVID-19 Vaccination and Strategies to Boost SARS-CoV-2 Immunity in People with Inborn Errors of ImmunitySemantic proximity Read ↗

Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity Read ↗

The characterization of CD8 + T-cell responses in COVID-19Semantic proximity Read ↗

Recent developments in the immunopathology of COVID-19Semantic proximity Read ↗

T-cell Immunity Against COVID-19 and UK Variant in Infected and Vaccinated IndividualsSemantic proximity Read ↗

Negligible impact of SARS-CoV-2 variants on CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell reactivity in COVID-19 exposed donors and vaccineesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.